Ligand Pharmaceuticals Incorporated Detailed Financials
Full historical quarterly statements
| Metric | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 51.7M | 59.7M | 115.5M | 47.6M | 45.3M | 42.8M | 51.8M | 41.5M |
| Cost of Goods Sold | 2.1M | -26.0M | 24.8M | 2.9M | 4.8M | 2.8M | 12.5M | -15.3M |
| Gross Profit | 49.6M | 85.7M | 90.6M | 44.7M | 40.5M | 40.0M | 39.3M | 56.9M |
| R&D Expenses | 2.1M | 3.5M | 21.0M | 6.6M | 50.1M | 4.4M | 5.7M | 5.4M |
| Operating Expenses | 32.3M | 65.6M | 35.7M | 36.3M | 76.7M | 49.6M | 36.2M | 76.0M |
| Operating Income | 17.4M | 20.0M | 54.9M | 8.4M | -36.2M | -9.6M | 3.1M | -19.1M |
| Other Income / Gains | -41.6M | 36.7M | 86.2M | 2.8M | -14.0M | -29.6M | -9.5M | -46.3M |
| Net Income | -13.3M | 44.8M | 117.3M | 4.8M | -42.5M | -31.1M | -7.2M | -51.9M |
| EPS (Diluted) | -0.67 | 2.27 | 5.99 | 0.25 | -2.21 | -1.64 | -0.39 | -2.88 |
| Reported Currency | USD | USD | USD | USD | USD | USD | USD | USD |
| Gross Profit Ratio | 0.96 | 1.436 | 0.785 | 0.939 | 0.893 | 0.934 | 0.759 | 1.369 |
| General And Administrative Expenses | 20.8M | 25.0M | 28.4M | 20.2M | 18.8M | 25.6M | 24.5M | 17.6M |
| Selling And Marketing Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Selling General And Administrative Expenses | 20.8M | 25.0M | 28.4M | 20.2M | 18.8M | 25.6M | 24.5M | 17.6M |
| Other Expenses | 9.3M | 37.1M | -13.8M | 9.5M | 7.8M | 19.6M | 6.0M | 53.0M |
| Cost And Expenses | 34.4M | 39.6M | 60.5M | 39.2M | 81.5M | 52.4M | 48.7M | 60.6M |
| Interest Income | 4.9M | 4.6M | 3.0M | 1.6M | 1.8M | 1.9M | 1.3M | 2.8M |
| Interest Expense | 0 | 0 | 0 | 1.2M | 867K | 883K | 741K | 1.3M |
| Depreciation And Amortization | 0 | 9.6M | 8.1M | 8.5M | 8.8M | 8.6M | 9.0M | 8.9M |
| Ebitda | 17.4M | 66.4M | 149.2M | 20.9M | -40.5M | -29.7M | 3.4M | -55.3M |
| Ebitdaratio | 0.336 | 1.113 | 1.292 | 0.439 | -0.894 | -0.693 | 0.066 | -1.331 |
| Operating Income Ratio | 0.336 | 0.336 | 0.476 | 0.177 | -0.799 | -0.225 | 0.061 | -0.46 |
| Income Before Tax | -24.3M | 56.8M | 141.1M | 11.2M | -50.2M | -39.2M | -6.3M | -65.4M |
| Income Before Tax Ratio | -0.469 | 0.952 | 1.222 | 0.236 | -1.107 | -0.916 | -0.122 | -1.574 |
| Income Tax Expense | -10.9M | 12.0M | 23.9M | 6.4M | -7.7M | -8.1M | 833K | -13.5M |
| Net Income Ratio | -0.258 | 0.751 | 1.016 | 0.102 | -0.936 | -0.726 | -0.138 | -1.25 |
| Epsdiluted | -0.67 | 2.12 | 5.68 | 0.24 | -2.21 | -1.64 | -0.39 | -2.88 |
| Weighted Average Shs Out | 19.9M | 19.7M | 19.4M | 19.3M | 19.2M | 19.0M | 18.4M | 18.0M |
| Weighted Average Shs Out Dil | 19.9M | 21.1M | 20.2M | 19.9M | 19.2M | 19.0M | 18.4M | 18.0M |